Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans

American Journal on Addictions

Volumn 23, Issue 3, 2014, Pages 288-293

  Arias, Albert J ^a,b   Gelernter, Joel ^a,b   Gueorguieva, Ralitza ^a,c   Ralevski, Elizabeth ^a,b   Petrakis, Ismene L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University Suite 200   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; DISULFIRAM; NALTREXONE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; DOPAMINE BETA MONOOXYGENASE; DRUGS USED IN THE TREATMENT OF ADDICTION; MU OPIATE RECEPTOR; NARCOTIC ANTAGONIST; OPRM1 PROTEIN, HUMAN;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ALLELE; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DRINKING BEHAVIOR; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OPEN STUDY; PHARMACOGENETICS; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VETERAN; CAUCASIAN; COMPLICATION; DRUG COMBINATION; FEMALE; GENETICS; HETEROZYGOTE; MENTAL DISORDERS; MIDDLE AGED; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOLISM; DIAGNOSIS, DUAL (PSYCHIATRY); DISULFIRAM; DOPAMINE BETA-HYDROXYLASE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME; VETERANS;

EID: 84898842319     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2014.12102.x     Document Type: Article

References (21)

1. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 2005; 293: 1617-1625.
2. Kranzler HR, Van Kirk J., Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol Clin Exp Res. 2001; 25: 1335-1341.
3. Srisurapanont M, Jarusuraisin N., Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005; (1): CD001867. Review. Update in: Cochrane Database Syst Rev. 2010; (12):CD001867. PMID: 15674887.
4. Arias AJ, Sewell RA., Pharmacogenetically driven treatments for alcoholism: Are we there yet ? CNS Drugs. 2012; 26: 461-476.
5. Mutschler J, Abbruzzese E, Witt SH, et al. Functional polymorphism of the dopamine beta-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. J Clin Psychopharmacol. 2012; 32: 578-580.
6. Tang YL, Epstein MP, Anderson GM, et al. Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. Eur J Hum Genet. 2007; 15: 878-883.
7. Tang Y, Buxbaum SG, Waldman I, et al. A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms. Biol Psychiatry. 2006; 60: 1034-1038.
8. Hess C, Reif A, Strobel A, et al. A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J Neural Transmembr. 2009; 116: 121-130.
9. Kalayasiri R, Sughondhabirom A, Gueorguieva R, et al. Dopamine beta-hydroxylase gene (DbetaH) -1021C → T influences self-reported paranoia during cocaine self-administration. Biol Psychiatry. 2007; 61: 1310-1313.
10. Kosten TR, Wu G, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: Disulfiram and dopamine beta-hydroxylase. Biol Psychiatry. 2013; 73: 219-224.
11. Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005; 57: 1128-1137.
12. First MB, Williams Janet BW, Spitzer Robert L, et al. Structured Clinical Interview for DSM-IV-TR axis I Disorders, Clinical Trials Version (SCID-CT). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2007.
13. Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998; 93: 713-727.
14. Sobell LC, Sobell MB., Timeline follow-back: A technique for assessing self-reported alcohol consumption. In:, Litten R, Allen J, editors. Measuring Alcohol Consumption. Totowa, NJ: The Humana Press; 1992.
15. Livak KJ, Flood SJA, Marmaro J, Giusti W, Deetz K., Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic-acid hybridization. PCR Methods Appl. 1995; 4: 357-362.
16. Gelernter J, Gueorguieva R, Kranzler HR, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: Results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007; 31: 555-563.
17. Kranzler HR, Armeli S, Tennen H, et al. A double-blind, randomized trial of sertraline for alcohol dependence: Moderation by age and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol. 2011; 31: 22-30.
18. Kohnke MD, Zabetian CP, Anderson GM, et al. A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: Evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry. 2002; 52: 1151-1158.
19. Saigusa T, Aono Y, Uchida T, et al. The alpha(1)-, but not alpha(2)-, adrenoceptor in the nucleus accumbens plays an inhibitory role upon the accumbal noradrenaline and dopamine efflux of freely moving rats. Eur J Pharmacol. 2012; 688: 35-41.
20. Blum K, Chen AL, Braverman ER, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 2008; 4: 893-918.
21. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008; 65: 135-144.